Assessing the long-term evolution of type 3 neovascularization in age-related macular degeneration using optical coherence tomography angiography

Cho, Han Joo; Lim, Seung Taek; Kim, Jaemin; Lee, Ji‐Hyun; Lee, Jun Young; Kim, Jong Woo

doi:10.1007/s00417-021-05163-7

Cited by 4 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As before, 16 we did not see vessels of choroidal origin in the sub–RPE-BL space, as reported for advanced type 3 MNV. 14 , 44 , 52 , 53 , 54 Nor did we see DCP-originating vessels penetrate through the BLamD and enter the sub–RPE-BL space. This depth of penetration was suggested as necessary for exudation.…”

Section: Discussionmentioning

confidence: 70%

Histology of Type 3 Macular Neovascularization and Microvascular Anomalies in Treated Age-Related Macular Degeneration

Berlin

Cabral²,

Chen³

et al. 2023

Ophthalmology Science

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 70%

Histology of Type 3 Macular Neovascularization and Microvascular Anomalies in Treated Age-Related Macular Degeneration

Berlin

Cabral²,

Chen³

et al. 2023

Ophthalmology Science

View full text Add to dashboard Cite

“…As before, 16 we did not see vessels of choroidal origin in the sub-RPE-BL space, as reported for advanced type 3 MNV. 14,44,[52][53][54] Nor did we see DCP-originating vessels penetrate through BLamD and enter the sub-RPE-BL space. This depth of penetration was suggested as necessary for exudation.…”

Section: Discussionmentioning

confidence: 80%

Histology of type 3 macular neovascularization and microvascular anomalies in treated age-related macular degeneration: a case study

Berlin

Cabral

Chen

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…However, several reasons could be attributed to the characteristics of type 3 MNV. Type 3 MNV is generally smaller 24 , resulting in rather minute exudation compared to other types of neovascular AMD 18 , 25 . In addition, the exudation and PED in type 3 lesions usually respond rapidly to treatment, since type 3 lesions are more sensitive to anti-VEGF therapy compared to other types of neovascular AMD 11 , 24 .…”

Section: Discussionmentioning

confidence: 99%

Impact of macular fluid features on outcomes of anti-vascular endothelial growth factor treatment for type 3 macular neovascularization

Yoon

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

We evaluated the impact of macular fluid features on visual and anatomical outcomes in type 3 macular neovascularization (MNV) patients treated with anti-vascular endothelial growth factor (VEGF). We retrospectively enrolled 89 eyes with type 3 MNV with at least 12 months of follow-up. All patients were treatment-naïve and received a monthly loading injection of anti-VEGF for three months, followed by further injections as required. The association of baseline macular morphology, including intraretinal fluid (IRF) and subretinal fluid (SRF), with visual and anatomical outcomes was analyzed. At baseline, IRF was present in all enrolled patients (100%), and SRF was present in 43.8% (39/89) of them. After 12 months of treatment, no significant difference was found in terms of best-corrected visual acuity (BCVA) and changes in central foveal thickness between the eyes with (39) and without (50) SRF at baseline. In addition, the proportion of improved or worsened (gain or loss of more than three lines in the BCVA) visual acuity at 12 months was not significantly different among the groups. Incidence of macular atrophy during the treatment showed no difference between the groups, regardless of the presence of SRF. In conclusion, the macular fluid morphology, specifically SRF, in type 3 MNV showed no significant correlation with visual and anatomical outcomes during anti-VEGF treatment.

show abstract

Assessing the long-term evolution of type 3 neovascularization in age-related macular degeneration using optical coherence tomography angiography

Cited by 4 publications

References 26 publications

Histology of Type 3 Macular Neovascularization and Microvascular Anomalies in Treated Age-Related Macular Degeneration

Histology of Type 3 Macular Neovascularization and Microvascular Anomalies in Treated Age-Related Macular Degeneration

Histology of type 3 macular neovascularization and microvascular anomalies in treated age-related macular degeneration: a case study

Impact of macular fluid features on outcomes of anti-vascular endothelial growth factor treatment for type 3 macular neovascularization

Contact Info

Product

Resources

About